Free Trial

Qiagen (QGEN) Stock Price, News & Analysis

-0.45 (-0.99%)
(As of 05/21/2024 ET)
Today's Range
50-Day Range
52-Week Range
773,169 shs
Average Volume
1.21 million shs
Market Capitalization
$10.27 billion
P/E Ratio
Dividend Yield
Price Target

Qiagen MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.56 Rating Score
13.4% Upside
$50.95 Price Target
Short Interest
1.32% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.50mentions of Qiagen in the last 14 days
Based on 5 Articles This Week
Insider Trading
Proj. Earnings Growth
From $2.09 to $2.25 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.17 out of 5 stars

Medical Sector

136th out of 921 stocks

Biological Products, Except Diagnostic Industry

15th out of 152 stocks

QGEN stock logo

About Qiagen Stock (NYSE:QGEN)

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

QGEN Stock Price History

QGEN Stock News Headlines

FDA Clears Qiagen's QIAstat-Dx Respiratory Syndromic Testing Panel
Qiagen Q1 2024 Earnings Preview
See More Headlines
Receive QGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Qiagen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
9 Analysts


Net Income
$341.30 million
Pretax Margin


Sales & Book Value

Annual Sales
$1.97 billion
Cash Flow
$3.07 per share
Book Value
$16.69 per share


Free Float
Market Cap
$10.26 billion
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Thierry Bernard (Age 59)
    CEO, MD & Member of Management Board
    Comp: $1.99M
  • Dr. Roland Sackers (Age 55)
    CFO, MD & Member of Management Board
    Comp: $1.07M
  • Mr. Antonio Santos
    Senior VP & Head of Global Operations
  • Mr. John Gilardi
    Vice President of Corporate Communications & Investor Relations
  • Ms. Stephany Foster (Age 45)
    Senior VP & Head of Human Resources
  • Dr. Thomas Schweins
    Senior Vice President of Life Science Business Area
  • Dr. Thomas Theuringer
    Senior Director & Head of External Communications
  • Mr. Jean-Pascal Viola
    Senior VP & Head of Molecular Diagnostics Business Area
  • Dr. Jonathan G. Sheldon Ph.D. (Age 52)
    Senior Vice President of Qiagen Digital Insights Business Area

QGEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Qiagen stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Qiagen in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" QGEN shares.
View QGEN analyst ratings
or view top-rated stocks.

What is Qiagen's stock price target for 2024?

9 Wall Street research analysts have issued 1 year price targets for Qiagen's shares. Their QGEN share price targets range from $43.30 to $60.00. On average, they anticipate the company's share price to reach $50.95 in the next year. This suggests a possible upside of 13.4% from the stock's current price.
View analysts price targets for QGEN
or view top-rated stocks among Wall Street analysts.

How have QGEN shares performed in 2024?

Qiagen's stock was trading at $44.7732 at the start of the year. Since then, QGEN stock has increased by 0.4% and is now trading at $44.94.
View the best growth stocks for 2024 here

Are investors shorting Qiagen?

Qiagen saw a decline in short interest in April. As of April 15th, there was short interest totaling 2,960,000 shares, a decline of 16.9% from the March 31st total of 3,560,000 shares. Based on an average trading volume of 1,010,000 shares, the short-interest ratio is currently 2.9 days. Currently, 1.3% of the shares of the stock are short sold.
View Qiagen's Short Interest

When is Qiagen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our QGEN earnings forecast

How were Qiagen's earnings last quarter?

Qiagen (NYSE:QGEN) posted its earnings results on Monday, April, 29th. The company reported $0.46 EPS for the quarter, topping analysts' consensus estimates of $0.44 by $0.02. The business had revenue of $459 million for the quarter, compared to the consensus estimate of $453.91 million. Qiagen had a trailing twelve-month return on equity of 12.59% and a net margin of 17.38%. Qiagen's revenue was down 5.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.53 EPS.

How often does Qiagen pay dividends? What is the dividend yield for Qiagen?

Qiagen declared a -- dividend on Monday, January 22nd. Shareholders of record on Wednesday, January 31st will be given a dividend of $1.3196 per share on Tuesday, January 30th. The ex-dividend date of this dividend is Tuesday, January 30th.
Read our dividend analysis for QGEN

When did Qiagen's stock split?

Qiagen's stock reverse split on Tuesday, January 30th 2024. The 24.25-25 reverse split was announced on Tuesday, January 30th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 97 shares after the split.

What guidance has Qiagen issued on next quarter's earnings?

Qiagen updated its FY 2024 earnings guidance on Monday, April, 29th. The company provided EPS guidance of 2.100- for the period, compared to the consensus estimate of 2.110. The company issued revenue guidance of $2.0 billion-, compared to the consensus revenue estimate of $2.0 billion.

What is Thierry Bernard's approval rating as Qiagen's CEO?

33 employees have rated Qiagen Chief Executive Officer Thierry Bernard on Thierry Bernard has an approval rating of 65% among the company's employees.

What other stocks do shareholders of Qiagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Qiagen investors own include NVIDIA (NVDA), QUALCOMM (QCOM), Gilead Sciences (GILD), Advanced Micro Devices (AMD), PayPal (PYPL), Netflix (NFLX), Pfizer (PFE), Cisco Systems (CSCO), Amgen (AMGN) and Lam Research (LRCX).

Who are Qiagen's major shareholders?

Qiagen's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.80%), Nuance Investments LLC (1.97%), Earnest Partners LLC (1.50%), BNP Paribas Financial Markets (0.77%), Allspring Global Investments Holdings LLC (0.74%) and Allspring Global Investments Holdings LLC (0.74%).

How do I buy shares of Qiagen?

Shares of QGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:QGEN) was last updated on 5/21/2024 by Staff

From Our Partners